CN Patent

CN120152984A — 治疗和/或预防日光性角化病的化合物及方法

Assigned to Enkang Pharmaceutical Technology Guangzhou Co ltd · Expires 2025-06-13 · 1y expired

What this patent protects

本申请涉及17β‑黄夹次甙乙或其药学上可接受的盐、外消旋体、立体异构体、对映异构体、非对映异构体、互变异构体、代谢物、溶剂化物、前体药物及其在治疗和/或预防日光性角化病的方法，其可以经皮渗透而能够直接作用于病变部分，在提高疗效的同时具有较高的安全性。

USPTO Abstract

本申请涉及17β‑黄夹次甙乙或其药学上可接受的盐、外消旋体、立体异构体、对映异构体、非对映异构体、互变异构体、代谢物、溶剂化物、前体药物及其在治疗和/或预防日光性角化病的方法，其可以经皮渗透而能够直接作用于病变部分，在提高疗效的同时具有较高的安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN120152984A
Jurisdiction
CN
Classification
—
Expires
2025-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Enkang Pharmaceutical Technology Guangzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.